Compare Johnson & Johnson (JNJ) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs ProShares UltraPro S&P500 — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while ProShares UltraPro S&P500 trades at $155.73 (market cap $5.55B). The key difference: Johnson & Johnson is far larger — about 111.4× ProShares UltraPro S&P500's market cap, and Johnson & Johnson pays a 2.09% dividend while ProShares UltraPro S&P500 pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and ProShares UltraPro S&P500 for 29 Days on average.
| JNJ | UPRO | |
|---|---|---|
Market Cap | $618.09B | $5.55B |
Volume | 6,050,983 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $278.43 | $157.66 |
52-Week Low | $186.00 | $89.29 |
Typical Hold Time | 129 Days | 29 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
UPRO trades at $153.19, down 1.3% on the day, with technical indicators showing a bullish moving average trend but neutral oscillators. The stock faces resistance at $155 and support at $151. Recent news highlights S&P 500 valuation concerns and expected profit growth deceleration from 35% in 2026 to 15% in 2027, creating mixed sentiment around the broader market environment.
The outlook for UPRO is influenced by broader market dynamics, with Wall Street expecting continued S&P 500 gains but facing headwinds from concentration risks and economic uncertainty. Key opportunities include potential year-end rallies, while risks involve market volatility and earnings growth slowdowns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
